Adm1n: Created page with "AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agon..."

2015-02-16T15:11:07Z

Created page with "AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agon..."

New page

AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective [[cannabinoid]] agonist, acting as a potent agonist at the[[ CB1]] receptor and a partial agonist at [[CB2]]. It has poor blood–brain barrier penetration, and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as [[WIN 55,212-2]]. A large number of related benzimidazole derived cannabinoid ligands are known.

==See also==

* [[AM-6545]]

* [[CB-13]]

AZ-11713908 - Revision history

Adm1n: Created page with "AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agon..."